Diamyd Medical, a Sweden-based company that develops precision medicine therapies for Type 1 Diabetes, announced on Monday that the US Food and Drug Administration (FDA) has withdrawn the partial clinical hold on the confirmatory Phase III trial DIAGNODE-3, assessing the safety and efficacy of the precision medicine and antigen-specific immunotherapy Diamyd in individuals recently diagnosed with type 1 diabetes.
Subsequent to the decision from the FDA, DIAGNODE-3 is approved to commence in the United States.
The FDA issued a partial clinical hold on the trial in September 2021, halting its commencement in the US. The company is to immediately resume the process of interacting with clinical sites and institutional review boards with the intention of including US clinical sites in the trial. The trial has been approved and is actively hiring patients in eight European countries.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults